Mesenchymal Stem Cells-Derived Exosomes Alleviate Acute Lung Injury by Inhibiting Alveolar Macrophage Pyroptosis
Stem Cells Translational Medicine · 15.04.2024 · 13 (4) · 371-386
DOI: 10.1093/stcltm/szad094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 13.02.2024. Verfasst von Peipei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, Institute of Respirato…. Hauptthemen laut MEDLINE: Exosomes, Acute Lung Injury, MicroRNAs, Mesenchymal Stem Cells. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Sciences, Science and Technology Innovation in Medicine.
Abstract (Originalsprache)
Acute lung injury (ALI) is an important pathological process of acute respiratory distress syndrome, yet there are limited therapies for its treatment. Mesenchymal stem cells-derived exosomes (MSCs-Exo) have been shown to be effective in suppressing inflammation. However, the effects of MSCs-Exo on ALI and the underlying mechanisms have not been well elucidated. Our data showed that MSCs-Exo, but not exosomes derived from MRC-5 cells (MRC-5-Exo), which are human fetal lung fibroblast cells, significantly improved chest imaging, histological observations, alveolocapillary membrane permeability, and reduced inflammatory response in ALI mice model. According to miRNA sequencing and proteomic analysis of MSCs-Exo and MRC-5-Exo, MSCs-Exo may inhibit pyroptosis by miRNAs targeting caspase-1-mediated pathway, and by proteins with immunoregulation functions. Taken together, our study demonstrated that MSCs-Exo were effective in treating ALI by inhibiting the pyroptosis of alveolar macrophages and reducing inflammation response. Its mechanism may be through pyroptosis-targeting miRNAs and immunoregulating proteins delivered by MSCs-Exo. Therefore, MSCs-Exo may be a new treatment option in the early stage of ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, National Clinical Re…
- Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China.
- Harbin Medical University, Harbin, People's Republic of China.
- Department of Obstetric Medicine, Tianjin Third Central Hospital, Tianjin, People's Republic of China.
- China Capital Medical University, Beijing, People's Republic of China.
- Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, People's Republic of China.
ORCID-Profile: Peipei Liu
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- Science and Technology Innovation in Medicine
Zitieren
APA
Liu, P., Yang, S., Shao, X., Li, C., Wang, Z., Dai, H., & Wang, C. (2024). Mesenchymal Stem Cells-Derived Exosomes Alleviate Acute Lung Injury by Inhibiting Alveolar Macrophage Pyroptosis. Stem Cells Translational Medicine, 13(4), 371-386. https://doi.org/10.1093/stcltm/szad094
Vancouver
Liu P, Yang S, Shao X, Li C, Wang Z, Dai H, et al. Mesenchymal Stem Cells-Derived Exosomes Alleviate Acute Lung Injury by Inhibiting Alveolar Macrophage Pyroptosis. Stem Cells Translational Medicine. 2024;13(4):371-386. doi:10.1093/stcltm/szad094
BibTeX
@article{Liu2024,
author = {Liu, Peipei and Yang, Shengnan and Shao, Xuecheng and Li, Chen and Wang, Zai and Dai, Huaping and Wang, Chen},
title = {Mesenchymal Stem Cells-Derived Exosomes Alleviate Acute Lung Injury by Inhibiting Alveolar Macrophage Pyroptosis},
journal = {Stem Cells Translational Medicine},
year = {2024},
volume = {13},
number = {4},
pages = {371--386},
doi = {10.1093/stcltm/szad094}
}
EUVIMED